ZYBT (Zhengye Biotechnology Holding) Short-Term Debt: $9.34 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZYBT Zhengye Biotechnology Holding Ltd ZYBT
20 GF Score
Price $1.98
! 5 Warning Signs
View Full Analysis

What is Zhengye Biotechnology Holding Short-Term Debt?

Zhengye Biotechnology Holding ZYBT +1.54% 20 Short-Term Debt is $9.34 Mil as of Dec. 2025. GuruFocus rates ZYBT with a GF Score™ of 20/100. The stock has 5 warning signs investors should review.

Zhengye Biotechnology Holding's Short-Term Debt for the quarter that ended in Dec. 2025 was $9.34 Mil.

Zhengye Biotechnology Holding's quarterly Short-Term Debt increased from Dec. 2024 ($11.21 Mil) to Jun. 2025 ($11.29 Mil) but then declined from Jun. 2025 ($11.29 Mil) to Dec. 2025 ($9.34 Mil).

Zhengye Biotechnology Holding's annual Short-Term Debt increased from Dec. 2023 ($11.19 Mil) to Dec. 2024 ($11.21 Mil) but then declined from Dec. 2024 ($11.21 Mil) to Dec. 2025 ($9.34 Mil).

Zhengye Biotechnology Holding Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Zhengye Biotechnology Holding Short-Term Debt Related Terms

Zhengye Biotechnology Holding Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Zhengye Biotechnology Holding's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhengye Biotechnology Holding Short-Term Debt Chart

Zhengye Biotechnology Holding Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
4.71 7.87 11.19 11.21 9.34

Zhengye Biotechnology Holding Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only 11.19 12.05 11.21 11.29 9.34
ZYBT
20GF Score
Zhengye Biotechnology Holding Ltd ZYBT
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $9.34 Mil mean?
Zhengye Biotechnology Holding (ZYBT) has a Short-Term Debt of $9.34 Mil as of Dec. 2025.
Is Zhengye Biotechnology Holding's Short-Term Debt too high?
Zhengye Biotechnology Holding's current Short-Term Debt is $9.34 Mil. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's Short-Term Debt compare to TLPH and CPHI?
Zhengye Biotechnology Holding's Short-Term Debt of $9.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Zhengye Biotechnology Holding's current Short-Term Debt is $9.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current Short-Term Debt of $9.34 Mil. The current Short-Term Debt is $9.34 Mil. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current Short-Term Debt is $9.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zhengye Biotechnology Holding Business Description

Address No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, Jilin City, CHN
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score

Get the complete analysis for ZYBT

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.98
Price